Peel Hunt restated their buy rating on shares of Udg Healthcare (LON:UDG) in a research note released on Monday morning, ThisIsMoney.Co.Uk reports.
Other equities analysts have also recently issued reports about the company. Liberum Capital reiterated a buy rating and set a GBX 884 ($11.55) price target on shares of Udg Healthcare in a report on Monday, February 4th. Barclays upgraded Udg Healthcare to an overweight rating and lowered their price target for the stock from GBX 770 ($10.06) to GBX 720 ($9.41) in a report on Thursday, April 4th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of Buy and an average target price of GBX 780.57 ($10.20).
LON UDG opened at GBX 658.50 ($8.60) on Monday. The firm has a market cap of $1.64 billion and a PE ratio of 439.00. The company has a debt-to-equity ratio of 27.53, a current ratio of 2.02 and a quick ratio of 1.80. Udg Healthcare has a twelve month low of GBX 545 ($7.12) and a twelve month high of GBX 950.50 ($12.42).
UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services in the Republic of Ireland, the United Kingdom, North America, and internationally. The company operates in two segments, Ashfield and Sharp. The Ashfield segment offers commercialization services for the pharmaceutical and healthcare industry in the areas of advisory, communications, and commercial and clinical services.
Read More: What causes a recession?
Receive News & Ratings for Udg Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Udg Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.